Genprex

Genprex has entered into an exclusive patent license agreement with UTHealth Houston for its REQORSA gene therapy to treat glioblastoma, expanding beyond its established lung cancer applications.

Genprex's Acclaim-3 trial, evaluating Reqorsa with Tecentriq for extensive stage small cell lung cancer (ES-SCLC), has advanced to Phase 2.

• Kiromic BioPharma's Deltacel T-cell therapy demonstrates disease stabilization in NSCLC patients, showing potential in advanced solid tumor treatment. • Achilles Therapeutics advances neoantigen reactive T-cell therapy trials for NSCLC and melanoma, observing improved T-cell persistence with enhanced conditioning. • Genprex reports positive results in two lung cancer trials for Reqorsa gene therapy, while discontinuing another, focusing on optimal patient cohorts. • Viral immunotherapy combo CAN-2409 improves survival in NSCLC patients unresponsive to anti-PD-L1 therapy, reactivating exhausted immune systems.

Genprex presented positive preclinical data for Reqorsa, a gene therapy targeting Ras inhibitor-resistant lung cancer, mesothelioma, and glioblastoma, showing increased TUSC2 uptake in tumor cells.

Genprex has entered a sponsored research agreement with the University of Michigan to study Reqorsa® gene therapy combined with ALK-inhibitors for ALK+ lung cancer.

Genprex's Reqorsa, combined with Tecentriq, advances to the highest dose group (0.12 mg/kg) in Phase 1 of the Acclaim-3 trial for ES-SCLC after SRC approval.

Genprex is expanding its research program for Reqorsa, an investigational immunogene therapy, to include mesothelioma, a cancer with limited treatment options.